454 Results (Page 1 of 19)
Japan Markets Research Reports
Japan ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market Analysis
Japan ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat polycystic kidney disease is driven by an increase in patients who require dialysis or renal failure. A significant factor influencing the growth rate of the polycystic kidney disease (PKD) drugs market is the rise in healthcare spending, which helps to improve its infrastructure. Major global players in ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market are Otsuka Pharmaceutical Co., Ltd., Regulus Therapeutics, Palladio Biosciences, Reata Pharmaceuticals, Inc., Galapagos NV, AceLink Therapeutics, Inc., Exelixis, Inc, XORTX Therapeutics Inc., Sanofi S.A., PanoTherapeutics, Inc.
Japan Myeloproliferative Disorders (MPD) Therapeutics Market Analysis
Japan Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.
Japan Skin Antiseptic Products Market Analysis
This report presents a strategic analysis of the Japan Skin Antiseptic Products Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Skin Antiseptic Products Market, offering unmatched value, accuracy and expert insights.
Japan ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market Analysis
The Japan ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market is projected to grow from $1.837 Bn in 2022 to $2.653 Bn by 2030, registering a CAGR of 4.70% during the forecast period of 2022 – 2030. Japan has a high level of awareness of ADHD and the availability of a wide range of treatment options, which leads to a high rate of diagnosis and treatment of ADHD. Some key players of the Japan ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market include Shire Japan, Novartis Pharma, Janssen Pharmaceutical, Pfizer Japan, Takeda Pharmaceutical Company, Eisai Co. Ltd.
Japan Leukocyte Adhesion Deficiency (LAD-I) Market Analysis
Japan Leukocyte Adhesion Deficiency (LAD-I) therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. An uncommon genetic condition called leukocyte adhesion deficiency (LAD-I) impairs the immune system's capacity to combat infections. There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. Vertex Pharmaceuticals, Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals, Inc., Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, and Sigma-Aldrich are major global players.
Japan Rheumatology Drugs Market Analysis
The Japan Rheumatology Drugs Market is projected to grow from $3.795 Bn in 2022 to $4.920 Bn by 2030, registering a CAGR of 3.30% during the forecast period of 2022-2030. Leading companies working on new treatments for rheumatoid arthritis include Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol-Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceutical
Japan Herpes Simplex Virus Therapeutics Market Analysis
Japan Herpes Simplex Virus Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Herpes simplex virus (HSV) is a common viral infection that can cause a range of diseases in humans. High Prevalence of HSV Infections, Increasing Awareness and Diagnosis, Continued research and development efforts, Technological advancements and Increasing healthcare expenditure, particularly in developed countries, provides a supportive environment for the growth of the HSV Therapeutics market. Social stigma surrounding herpes, Drug-resistant HSV strains provided by limited treatment options are restraining factors in herpes simplex therapeutics market. GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Novartis AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd. Are global key players in herpes simplex therapeutics market.
Japan Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis
Japan Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.
Japan Charcot-Marie-Tooth Disease (CMT) Therapeutics Market Analysis
Japan Charcot-Marie-Tooth Disease (CMT) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The majority of hereditary peripheral neuropathies are Charcot-Marie-Tooth (CMT) illness, commonly referred to as hereditary motor and sensory neuropathy (HMSN). Genes that support or generate proteins important in the construction and operation of the myelin sheath or the peripheral nerve axon are mutated, leading to CMT. An increase in genetic illnesses will result in more innovations being made in this area, which will enhance market growth because there are many genes that cause these problems. The above-mentioned forecast period will witness the emergence of the market for Charcot Marie-Tooth disease due to multiple prospects that will be heightened by the rising focus on targeted therapies and the favorable government regulations. Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp., Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. are some of the major players in the Charcot Marie Tooth Disease Market.
Japan Batten's Disease (CLN-2) Therapeutics Market Analysis
Japan Batten?s Disease (CLN-2) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neuronal Ceroid Lipofuscinosis (NCL), often known as Batten disease, is a rare and severe autosomal recessive neurodegenerative lysosomal storage condition brought on by cellular buildup of aberrant auto-fluorescent lipoproteins (lipofuscin). Seizures and a progressive loss of movement, verbal, visual, and cognitive abilities are features of this neurodegenerative condition that primarily affects the nerve system. Research advancements in nanotechnology could result in the creation of fresh therapies that would benefit persons who suffer from this ailment. Additionally, it is a paediatric brain condition that is extremely rare yet progresses quickly. As a result, Batten's Disease may be exacerbated by the predicted rising prevalence of disease. Therapeutics market (CLN-2). The market for Batten's Disease (CLN-2) Therapeutics is constrained by a lack of treatment and symptoms that are challenging to identify. Regenxbio, Polaryx Therapeutics and Abeona Therapeutics are some of the key players in the market.
Japan ATTR (Transthyretin Amyloidosis) Therapeutics Market Analysis
Japan ATTR (Transthyretin Amyloidosis) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An rare and progressive condition known as ATTR (Transthyretin Amyloidosis) is characterised by the buildup of aberrant proteins in the body, including misTTR. The market for treatments for transthyretin amyloidosis is primarily driven by the expansion of the population and the availability of favourable reimbursement programmes. The market is predicted to increase as a result of strategic actions done by major players such raising knowledge of the target conditions like ATTR and the long-term advantages of treatments that are currently accessible. The market for treating transthyretin amyloidosis is currently constrained by a number of factors, including low awareness of the condition in developing nations, misdiagnosis of the condition, high costs of disease diagnosis and treatment, the lack of adequate clinical trials, and the absence of effective medications. Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and numerous others are global competitors in the ATTR (Transthyretin Amyloidosis) market.
Japan Ankylosing Spondylitis Therapeutics Market Analysis
Japan Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
Japan Adrenoleukodystrophy (ALD) Therapeutics Market Analysis
Japan Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Japan Adrenoleukodystrophy (ALD) drugs market.
Japan Dental Caries Detectors Market Analysis
The Japan Dental Caries Detectors Market was valued at $14.2 Mn in 2023 and is predicted to grow at a CAGR of 9.4% from 2023 to 2030, to $26.6 Mn by 2030. Japan Dental Caries Detectors Market is growing due to Increasing Dental Awareness and Education, Government Initiatives and Funding and Technological Advancements. The market is primarily dominated by players such as Acteon Group, AdDent Inc., Air Techniques Inc, Dentlight Inc., DEXIS, Sirona Dental Systems, Dentsply Sirona, KaVo Kerr, Ivoclar Vivadent, Planmeca Oy, Adec Technologies, 3M ESPE, Morita Corporation, Woodpecker Medical Instruments Co., Softdent.
Japan Clinical Nutrition for Diabetes Care Market Analysis
The Japan Clinical Nutrition for Diabetes Care Market was valued at $133.64 Mn in 2023 and is predicted to grow at a CAGR of 5.28% from 2023 to 2030, to $191.58 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Abbott Nutrition, Eli Lily, Danone, AgaMatrix Inc., and among others.
Japan Pharmacy Automation Device Market Analysis
The Japan Pharmacy Automation Device Market was valued at $341.9 Mn in 2023 and is predicted to grow at a CAGR of 10.4% from 2023 to 2030, to $683.4 Mn by 2030. Japan Pharmacy Automation Device Market is growing due to Reducing Human Errors, Adoption of Electronic Health Records, and Increased Demand for Pharmaceuticals. The market is primarily dominated by players such as Omron Corporation, Panasonic Corporation, Amerisource Bergen Corporation, Accu-Chart Plus Healthcare Systems, Omnicell, Inc., and McKesson Corporation.
Japan Cardiac Pacemakers Market Analysis
The Japan Cardiac Pacemakers Market was valued at $251.55 Mn in 2023 and is predicted to grow at a CAGR of 3.7% from 2023 to 2030, to $324.40 Mn by 2030. The key drivers of this industry include the aging population, healthcare infrastructure, and increased preference for minimally invasive processes. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.
Japan Mental Health Apps Market Analysis
The Japan Mental Health Apps Market was valued at $385.38 Mn in 2023 and is predicted to grow at a CAGR of 15.7% from 2023 to 2030, to $1069.61 Mn by 2030. The key drivers of this industry include increasing smartphone penetration, rising incidences, and rising interest in preventive care. The industry is primarily dominated by players such as HeadSpace, Calm, Awarefy, and Mindfulness among others.
Japan Clinical Nutrition for Cancer Care Market Analysis
The Japan Clinical Nutrition for Cancer Care Market was valued at $349.95 Mn in 2023 and is predicted to grow at a CAGR of 5.54% from 2023 to 2030, to $510.42 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increasing risk of malnutrition in oncology patients, and advancements in nutritional products. The prominent players of the Japan Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, MediFood, and Fresenius Kabi, among others.
Japan Gram-Negative Infection Therapeutics Market Analysis
The Japan Gram-Negative Infection Therapeutics Market was valued at $924.6 Mn in 2023 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030 to $1427.4 Mn by 2030. The primary factors fueling this market growth include the increasing challenge of antimicrobial resistance (AMR), the aging demographics, and government efforts. Major players in Japan's market include Eli Lilly and Company and Bayer AG, among others.
Japan Home Infusion Therapy Market
The Japan Home Infusion Therapy Market was valued at $2235.2 Mn in 2023 and is predicted to grow at a CAGR of 8.6% from 2023 to 2030, to $3982.3 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the Japan Home Infusion Therapy Market are Terumo Corporation, Nipro Corporation, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.
Japan Hepatitis A Therapeutics Market Analysis
The Japan Hepatitis A Therapeutics Market was valued at $45.82 Mn in 2023 and is predicted to grow at a CAGR of 2.7% from 2023 to 2030 to $55.22 Mn by 2030. The market's growth is fuelled by an increase in the prevalence of Hepatitis A, evidenced by 162 confirmed cases and the inaugural report of a death from an acute hepatitis variant as of 2023. Leading companies in this sector include Takeda and GlaxoSmithKline (GSK), among others.
Japan Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis
Japan Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc
Japan Pharmaceutical Market Analysis
This report presents a strategic analysis of the Japan Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Japan Pharmaceutical Market, offering unmatched value, accuracy and expert insights.
Japan Mucopolysaccharidosis I (MPS-I) Therapeutics Market Analysis
Japan Mucopolysaccharidosis I (MPS-I) therapeutics market is projected to grow from $0.15 Bn in 2022 to $0.25 Bn by 2030, registering a CAGR of 6.4% during the forecast period of 2022-30. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in this market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.